baber/WOPTO huggingface dataset:
Patent DE-102006054492-C5 (DE)
Inventor: CLAUS ARMIN
IPC: G06K7/10
Filed: 2006-11-18
Granted: 2019-05-23
Abstract: The reader (1) has a housing, where optical and electronic components (3, 4) and an electrical heating unit are arranged with a heat guiding body (6). The heating unit is connected with the heat guiding body in a heat conductive manner. The heat guiding body is formed by a retainer bracket (5) for retaining the components. The components are connected with the retainer bracket in a heat conductive manner.
Patent RU-2259825-C9 (RU)
Inventor: DENISENKO P P
IPC: A61P33/02
Filed: 2001-06-18
Granted: 2006-04-10
Abstract: FIELD: medicine, veterinary science. 
     SUBSTANCE: a new group of compounds, such as: 1) 1.3-benzodixole-5-β-nitroethylene  
       , 2) 1.3-benzodioxole-5-β-nitropropylene 
       , 3)benzimidazole-5-β-nitropropylene 
       , 4) 2-methylbenzimidazole-5-β-nitroethylene 
       , 5) benzoxazole-5-β-nitroethylene 
       , 6) 2-methylbenzoxazole-5-β-nitropropylene 
        has been suggested to protect against the agents of bacterial, protozoan and fungoid nature. Compounds are being the derivatives of heteronitroalkenes (dioxoles, oxazoles, imidazoles) with below-mentioned structural formulas being efficient to gram-positive bacteria and gram-negative aerobes, fungi of Candida, Trichophyton and other types, trichomonads. They could be applied at treating wound infections, fungoid lesions, septic states, pneumonia, trachoma, ornithosis, salmonellosis. 
     EFFECT: higher efficiency of protection. 
     5 cl, 5 tbl
Patent DK-60488-D0 (DK)
Inventor: SANTESSON STEFAN
IPC: H04L9/20
Filed: 1988-02-05
Abstract: PCT No. PCT/SE86/00275 Sec. 371 Date Feb. 2, 1989 Sec. 102(e) Date Feb. 2, 1989 PCT Filed Jun. 9, 1986 PCT Pub. No. WO87/07796 PCT Pub. Date Dec. 17, 1987.A ciphering system comprises a ciphering device having an input for a sequence of bits to be ciphered, and output for the ciphered bit sequence, and a mixing unit connected between the input and the output. The mixing unit receives both the bit sequence to be ciphered and a sequence of code bits for ciphering the bit sequence and, by a mixing operation, generates the ciphered bit sequence. The output of the mixing unit is connected to a first code unit for generating code bits. The first code unit comprises a memory addresses with bits from the ciphered bit sequence. The first code unit is furthermore connected to a second code unit, which comprises a memory containing code bits and the output of which is connected to the mixing unit. The deciphering device of the ciphering system is conceived in the same manner as the ciphering device, with the exception that the input of the code unit receives input signals from the input of the deciphering device.
Patent HU-910707-D0 (HU)
Title: Preparation of regulated emission of active substance and process for manufacturing it
Inventor: CARLI FABIO
IPC: A61P31/04
Filed: 1991-03-05
Abstract: The described therapeutic compositions with controlled release of medicaments comprise a medicament loaded onto particles of a crosslinked non-ionic polymer insoluble but swellable in water, using either swelling with solutions of the medicament or high-energy co-grinding methods. The medicament-loaded particles are coated with a polymers film able to control medicament release, to obtain a prolonged release of the medicament (even exceeding 24 hours) while maintaining high bioavailability.
Patent DK-175989-D0 (DK)
Inventor: DORNER FRIEDRICH
IPC: C12N5/00
Filed: 1989-04-12
Abstract: Proteinaceous material, including post-translationally modified proteins such as the vitamin K dependent blood factors can be produced by growing animal cells containing a recombinant avipox virus expression vector expressing foreign DNA coding for the proteinaceous material and harvesting the proteinaceous material. The recombinant avipox virus can be prepared by recombining an avipox virus with a plasmid including at least one replicon, at least one selection marker, at least one cloning site , and at least one promoter in which the promoter and the cloning sites are flanked by DNA sequences of an avipox virus. Foreign DNA can be inserted in the cloning site.
Patent DK-183087-D0 (DK)
Inventor: LAGAS JAN ADOLF
IPC: B01J23/86
Filed: 1987-04-10
Abstract: The invention is directed to a process for the recovery of sulfur from a hydrogen sulfide containing gas, which comprises oxidizing hydrogen sulfide with oxygen, and then reacting the product gas of this oxidation further by using at least two catalytic stages, in accordance with the equation: 2H2S + SO2 2H2O + 3/n Sn. In order to improve the process and the process control, the invention is characterized in that the H2S concentration in the gas leaving the last catalytic stage (17) is controled (23) to have a value ranging between 0.8 and 3% by volume by reducing the quantitiy of combustion or oxidation air passed to the oxidation stage (2) and/or causing a portion of the hydrogen sulfide containing feedstock gas to bypass (25) the oxidation stage and to be added to the gas flowing to a catalytic stage.
Patent DK-203787-D0 (DK)
Inventor: STOLTZ EDWIN I
IPC: A61K47/08
Filed: 1987-04-22
Abstract: Compositions and methods for the nasal administration of drugs with reduced nasal irritation are disclosed.
Patent DK-239789-D0 (DK)
Inventor: WEMPLE JAMES NORTON
IPC: C07D401/04
Filed: 1989-05-17
Abstract: An improved process for the preparation of 5-amino-7-(substituted-amino)-quinoline-3-carboxylic acids, having known antibacterial activity, is described wherein a 5-fluoro-7-(protected and substituted-amino)quinoline-3-carboxylic acid is converted to a 5-protected amino compound and where both protected amino groups are simultaneously removed to give the desired product.
Patent DK-351583-D0 (DK)
Inventor: KUN LESLIE CHARLES
IPC: F16C17/00
Filed: 1983-08-01
Abstract: A bearing system for high-speed rotary machinery wherein shaft support, flexible support and viscous damping are provided by separate and distinct mechanisms each of which can be adjusted independently of the other two.
Patent DK-383383-D0 (DK)
Inventor: ROY ASOK KUMAR
IPC: C12Q1/26
Filed: 1983-08-22
Abstract: A process for the production of a diagnostic device which is envisaged, in particular, for the detection of a pathologically increased concentration of dehydrogenases in fluids of humans, animals or plants and consists of a carrier and a substance mixture, in which, in each case with exclusion of UV radiation, the substance mixture, which has been adjusted to a pH value in the acid range, is brought into contact, in liquid form, with the carrier and the combination of carrier and substance mixture is subsequently dried and then enclosed in a packaging casing which is opaque to light of higher energy than red light. The process has the peculiarity that the dried combination of carrier and substance mixture in the packaging casing is securely sealed against entry of air and moisture. The device thus produced can be stored for a long time before use, without its ability to function being substantially changed.
Patent DK-387488-D0 (DK)
Inventor: BOGDANOV BORISLAV
IPC: C01B6/04
Filed: 1988-07-11
Abstract: Organic-solvent soluble magnesium hydrides of the formulas <CHEM> are prepared by catalytically hydrogenating finely powdered magnesium, optionally in the presence of a magnesium halide, in an organic solvent in the presence of their MgH2-free counterparts in which Q is an alkyl, alkenyl, alkoxy, dialkylamide, aralkyl, aryl or diarylamide group, each with up to 18 carbon atoms. R is an alkenyl, aralkyl or aryl group, each with up to 18 carbon atoms,  X is chlorine, bromine, or iodine,  - @@ @ -> is a chelating ligand,  E is -CH2, -N(R)- or -O-,  @ @@ is an alkylene radical of the formula -(CH2)p, D is a dialkylamide, diarylamide or alkoxy group, each with up to 18 carbon atoms,  M is aluminum or boron,  m is 1, 2, or 3, and 1 < n </= 50.
Patent DK-398185-D0 (DK)
Inventor: HEIMBURGER NORBERT
IPC: C12P21/02
Filed: 1985-08-30
Abstract: The process allows a pasteurised preparation of blood clotting factor VIII, which is virtually free of immunoglobulins, isoagglutinins, fibronectin and coagulable fibrinogen, to be obtained. A preparation of this type can be used to treat disturbances of blood clotting.
Patent DK-494884-D0 (DK)
Inventor: LEIPOLD DIANNE PATRICIA
IPC: A61Q11/00
Filed: 1984-10-16
Abstract: Disclosed are transparent dentifrice compositions comprising a humectant, a vehicle for the humectan, a finely divided dental abrasive, a silica thickener, and a hydrophobically modified hydroxyethyl cellulose thickening and gelling agent.
Patent DK-568486-D0 (DK)
Inventor: SZENTMIKLOSI PETER
IPC: A61K31/40
Filed: 1986-11-26
Abstract: The gel contains up to 30%, preferably 5-30% primycin and N-methyl-2-pyrrolidone (NMP), preferably 95-70% NMP, and also contains one or more antibacterial agents, preferably antibiotics.
Patent NO-870371-D0 (NO)
Inventor: FRANCOIS ALFRED
IPC: B01D53/26
Filed: 1987-01-29
Abstract: Device for drying moist air, comprising, in an enclosure (1) provided with openings (5, 6) for the admission and removal of air, a receptacle (10) for a solid desiccant and, under the latter, a layered structure (19) of superposed mats of a filter medium.
Patent NO-872502-D0 (NO)
Inventor: ROBINSON GRAHAM ERNEST
IPC: C07F7/18
Filed: 1987-06-16
Abstract: An improved process for preparing cephalosporins having a 7-position substituent of the formula:- <CHEM> wherein R<a> and R<b> represent hydrogen or alkyl or are joined to form a C3-5 cycloalkyl group, which comprises reacting a 7-amino cephalosporin with a compound of the formula:- <CHEM> wherein R<4> is hydrogen or an amino protecting group, R<1>, R<2> and R<3> are alkyl, aryl or arylalkyl and R<5> is the residue of a displaceable thioester group (R<5>SCO-) and subsequently removing the silyl group and, if necessary, the amino protecting group.
Patent NO-874834-D0 (NO)
Inventor: DAVIES ROY VICTOR
IPC: C07D495/04
Filed: 1987-11-19
Abstract: Novel 7(4H)-thieno[3,2-b]pyridinones of the formula I, <CHEM> wherein R is lower alkyl, and R1 is hydrogen, lower alkyl, lower alkoxy, halo, trifluoromethyl, or phenyl optionally substituted with one or two substituents selected from halo, lower alkyl, lower alkoxy and trifluoromethyl. The compounds are useful in the treatment of cardiovascular diseases. Pharmaceutical compositions containing the novel compounds and processes for preparing the novel compounds are also described.
Patent NO-901299-D0 (NO)
Inventor: ARONOFF MARVIN SAUL
IPC: B32B27/08
Filed: 1990-03-21
Abstract: Biodegradable composite films comprising a starch containing blended polymeric film and a barrier material coated or laminated to the blended film. The use of such composite films in ostomy pouches and other medical products is described. Also described is an ostomy pouch construction in which an adhesive label is affixed to the pouch so as to reduce the escape of odor from the stomal aperture.
Patent NO-903330-D0 (NO)
Inventor: GARNHAM DAVID
IPC: F16K27/00
Filed: 1990-07-26
Abstract: A valve assembly has a body portion (11) which can be removably receivable in a receptacle (10). The body carries the valve element such as a gate which controls fluid flow through a flowpath in the body. The openings of a flowpath in the receptacle accommodate annular sealing members (23, 24) which are movable axially in the openings. Means such as a lever arrangement (32, 33) are coupled to each sealing member and are contactable by the body (11) on its insertion in the receptacle such that the sealing members are moved axially toward the body to seal around the flowpath openings of the body.
Patent NO-904923-D0 (NO)
Inventor: HOLTON ROBERT A
IPC: A61P35/00
Filed: 1990-11-13
Abstract: Process for the preparation of a taxol intermediate comprising contacting an alcohol with an oxazinone having the formula: <CHEM> wherein R1 is aryl, heteroaryl, alkyl, alkenyl, alkynyl or OR7 wherein R7 is alkyl, alkenyl, alkynyl, aryl or heteroaryl; R2 and R5 are independently selected from hydrogen, alkyl alkenyl, alkynyl, aryl, heteroaryl, and OR8 wherein R8 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or hydroxyl protecting group; and R3 and R6 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl and heteroaryl.
Patent NO-905505-D0 (NO)
Inventor: RIVIER JEAN EDOUARD FREDERIC
IPC: C07K14/60
Filed: 1990-12-20
Abstract: The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans and also resist enzymatic degradation in the body. The peptides have the sequence: (B)R1-R2-R3-Ala-(Q1)R5-Phe-Thr-R8-Ser(Q2)R10-Arg-R12-(Q3)R13-Leu-R15-G ln-(Q4)Leu-R18-(Q5)Ala-Arg-R21-(Q6)R22-(Q7)Leu-R24-R25-(Q8)R26-(Q9)R27 -R28-Arg-Gln-Gln-Gly-Glu-R34-Asn-Gln-Glu-R38-R39-R40-Arg-R42-R43-R44 wherein R1 is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, CaMe, NaMe, desamino, Ac or For; R2 is Ala, D-Ala, NMA or D-NMA; R3 is Asp or D-Asp; R5 is Ile or Leu; R8 is Ser, Asn, Lys, Arg, Asp or Glu; R10 is Tyr, D-Tyr or Phe; R12 is Arg or Lys; R13 is Ile, Val, Leu or Ala; R15 is Gly or Ala; R18 is Ser or Tyr; R21 is Lys, D-Lys, Arg or D-Arg; R22 is Leu, Ile, Ala or Val; R24 is Gln or His; R25 is Asp or Glu; R26 is Ile or Leu; R27 is Met, D-Met, Ala, Nle, Ile, Leu, Nva or Val; R28 is Asn or Ser; R34 is Ser or Arg; R38 is Arg or Gln; R39 is Gly or Arg; R40 is Ala or Ser; R42 is Phe, Ala or Val; R43 is Asn or Arg; R44 is a natural amino acid; Q1-Q9 are either H or CaMe, provided however that one of Q1-Q9 is CaMe. These peptides may also be used diagnostically, and the C-terminus can be shortened to residue-29.
Patent NO-914389-D0 (NO)
Inventor: AYER ATUL DEVDATT
IPC: A61K9/22
Filed: 1991-11-11
Abstract: A dispenser is disclosed for delivering a beneficial ionophore to an animal. The dispenser comprises (1) a semipermeable housing defining an internal space, (2) at least one composition comprising an ionophore and a pharmaceutically acceptable carrier in the space, (3) an expandable hydrophilic composition in the space, (4) a dense member in the space, and (5) a passageway in the housing for delivering the ionophore from the dispenser.
Patent NO-914893-D0 (NO)
Inventor: SAGE JR BURTON H
IPC: A61N1/30
Filed: 1991-12-12
Abstract: An iontophoretic drug delivery device (20) having electrode renewing features includes a housing (21) having a first electrode (22), a second electrode (23), a circuit (26) for providing electrical communication between the first and second electrodes (22,23) and a source of current (27). Control means (S,28) is provided for effecting the amount of current passing between the electrodes (28,33). A removable electrolyte reservoir (29) is capable of holding electrolyte (31) and removably engaging the housing (21) so that one of the electrodes can contact electrolyte contained within the reservoir (29). A removable active agent reservoir (37) is capable of holding an active agent (40) for iontophoretic delivery. The active agent reservoir (37) is capable of removably engaging the housing (21) so that the active agent contacts one of the electrodes.
Patent NO-961110-D0 (NO)
Inventor: THURNER HANS
IPC: B22D17/14
Filed: 1996-03-19
Abstract: The prodn. of shaped metal components, comprises pressing a thixotropic metal bar (20) by means of a piston (16) from a filler chamber (12) into the die space (30), which is evacuated at least up to the instant of entry of the metal into this space. Also claimed is the appts. for performing the above method.
Patent NO-964081-D0 (NO)
Inventor: SPIRA JACK
IPC: A61K47/42
Filed: 1996-09-27
Abstract: PCT No. PCT/SE95/00348 Sec. 371 Date Sep. 17, 1996 Sec. 102(e) Date Sep. 17, 1996 PCT Filed Mar. 31, 1995 PCT Pub. No. WO95/26750 PCT Pub. Date Oct. 12, 1995The present invention relates to a pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising coagulation factor VIII or factor IX and use thereof for manufacture of a medicament for treating haemophilia A or B. The formulation comprises coagulation factor VIII or factor IX with an activity of at least 200 IU/ml and an additive increasing the bio-availability of factor VIII or factor IX. Tests with factor VIII gives a therapeutic level of active factor VIII in the blood stream for a surprisingly long period of time after subcutaneous, intramuscular or intradermal administration. The factor VIII is suitably a highly purified recombinant factor VII, and preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.
Patent NO-985749-D0 (NO)
Inventor: BAKER GARY
IPC: C08L83/04
Filed: 1998-12-08
Abstract: The emulsion comprises: 1) at least one resin M alpha D beta T gamma Q delta (OR) epsilon  (I) where: M=R<1>R<2>R<3>SiO1/2, D1 = R<4>R<5>SiO2/2 T = R<6>SiO3/2 Q = SiO4/2; 2) the reaction product between: 2a) one or several aromatic amines or polyfunctional aliphatics from 2 to 25 carbon atoms; 2b) one or several carboxylic acids or anhydrides containing 3 to 22 carbon atoms; 2c) at least one cross-linking agent which is a water-soluble metal complex. The invention is useful for waterproofing surfaces, in particular building materials paricularly stone, cement, concrete, mortar, bricks, tiles, wood, in which the above emulsion is used.
Patent GB-0024694-D0 (GB)
Title: Connection set-up in a communication system
IPC: H04L12/56
Filed: 2000-10-09
Abstract: In a communication system a procedure is initiated to establish a communication connection for a user equipment A data bearer may be established via one or more nodes of the communication system for the user equipment before the communication connection procedure is completed. An instruction is signalled to at least one of the nodes associated with the data bearer to prevent transportation of data to or from the user equipment by means of the data bearer. Based on the instruction, transportation of data to or from the user equipment is prevented until said communication connection establishment procedure has been completed. According to a further aspect, an indication is signalled to at least one of the nodes that the communication connection establishment procedure is completed. Charging record means associated with charging of data transportation prior said completion are closed in response to said signal.
Patent GB-0117834-D0 (GB)
Title: Gasket
IPC: F04B35/04
Filed: 2001-07-21
Abstract: A head gasket (5) is disclosed for a reciprocating compressor (1) that comprises a cylinder head (3) and a main body (2) containing a piston assembly (16) and piston valve means (22), the head gasket (5) being formed with fluid channel means (40,91), the arrangement being such that, in use, the fluid channel means (40,91) substantially prevents the piston valve means (22) becoming stuck. In a first embodiment of the invention the fluid channel means is a recess (40) formed by a cut-out (30) extending through the head gasket(5) and a portion of an inner surface of the cylinder head (3).   In a second embodiment of the present invention the fluid channel means is formed by a raised portion (91) that extends in a direction away from a planar surface of the head gasket (5). <IMAGE>
Patent GB-0128925-D0 (GB)
Title: Method of forming a recess in a body
IPC: B24B19/02
Filed: 2001-11-29
Abstract: A method of forming a recess in a body (10; 24) having a cylindrical surface, and in particular a metering valve component, utilises a grinding wheel (32) having a first axis (33), preferably a drive axis, and a circumferential surface (34) concave to a second axis (37) that is substantially orthogonal to the first axis (33). The grinding wheel (32) also includes first and second opposing radial surfaces (36, 38) of substantially planar form. At least a portion of the circumferential surface (34) of the grinding wheel (32) is engaged with an outer surface of the body (10; 24) and the grinding wheel (32) is rotated about the drive axis (33) to cause a region of the body (10; 24) to be ground, thereby to define a recess (40; 46) in the body having a periphery (42; 48) at the cylindrical surface including at least two substantially square corners (41a, 41b, 41c, 41d; 49a, 49b) and at least one pair of substantially parallel facing edges (43a, 43b, 43c, 43d; 47a, 47b). The method is conveniently used to provide an opening or port of at least partially square or rectangular form in a cylindrical body such as a metering valve member (24) or a metering valve sleeve (10) of a metering valve arrangement. <IMAGE>
Patent GB-0207975-D0 (GB)
Title: Isolating nucleic acid
IPC: C07H21/04
Filed: 2002-04-05
Abstract: A process for isolating nucleic acid from a nucleic acid-containing sample, which comprises: (a) providing a chaotrope; (b) providing a nucleic acid binding solid phase capable of binding nucleic acid in the presence of the chaotrope; (c) providing a source of NH4+ or NH3; (d) contacting the sample with the nucleic acid binding solid phase in the presence of a liquid phase comprising the chaotrope and the NH4+ or NH3; and (e) optionally separating the solid phase with the nucleic acid bound thereto from the liquid phase.
Patent GB-0209286-D0 (GB)
Title: Adjustable grass treatment apparatus
IPC: A01B73/04
Filed: 2002-04-24
Abstract: A grass treatment apparatus (10) which is adapted to be coupled with a propelling vehicle in order to be movable over the ground and which mounts a plurality of grass treatment units (14, 15, 16, 17, 18, 21 and 22) which are engageable with the ground in order to carry out required grass treatment operations, said apparatus comprising:  a main frame (11) having mountings (12, 13) by which the apparatus can be coupled with a propelling vehicle; a grass treatment unit (14, 15, 16) mounted on the main frame (11); a side frame (20) adjustably mounted on the main frame (11), and having a grass treatment unit (21, 22) mounted thereon; a mounting recess (23) provided in the main frame (11) for receiving the side frame (20); and a power-operated device coupling the side frame (20) to the main frame (11) and operative to adjust the side frame (20) between an outwardly deployed position in which it is laterally spaced from the main frame (11) so that the treatment units can operate throughout an extended width provided by the main frame (11) and the side frame (20) lying one beside the other, and an inwardly deployed position in which the side frame (20) is received by said mounting recess (23) so that the treatment units are located one behind the other and operate throughout a reduced width provided by the main frame (11) only.  <IMAGE>
Patent GB-0218224-D0 (GB)
Title: Iris diaphragm
IPC: G03B9/06
Filed: 2002-08-06
Abstract: An iris diaphragm comprising an annular base, an annular rotatable element and a number of leaves which can be mounted to form a variable aperture, each leaf extending between the base and element and being connected thereto in a pivotal relationship, is characterised in that a first end of each of said leaves is pivotally connected to an opening provided on the element or base by means of a burst hole joint, and a second end of each of said leaves being rotatably secured in a sliding relationship to a slide provided on the base or the element by means of a slide pin secured to the leaf. <IMAGE>
Patent GB-0413005-D0 (GB)
Title: Ligand
IPC: C07K14/475
Filed: 2004-06-11
Abstract: A method of promoting the differentiation of a mammary cell, the method comprising contacting the mammary cell with Neuregulin-3 (Nrg3) or a variant thereof which has mammary cell differentiation activity. A method of producing mammary tissue in vitro, the method comprising culturing cells in a 3D culture matrix and contacting the cells with Nrg3 or a variant thereof which has mammary cell differentiation activity. A method of preventing breast cancer in an individual, the method comprising administering to the individual Nrg3 or a variant thereof which has mammary cell differentiation activity.